For patients uncontrolled on multiple daily injections of insulin. A quick-start guide for your practice ALL-DAY CONTROL WITH

Transcription

1 For patients uncontrolled on multiple daily injections of insulin A quick-start guide for your practice

2 Dosing guidance 1,* V-Go: 3 options 1 For initiating V-Go in patients switching from MDI The majority of patients are started on V-Go 20 or V-Go 30 2 < 200 lbs lbs > 250 lbs V-Go Option Preset Basal Insulin Rate Over 24 Hours + Available Prandial Insulin = Total Available Insulin V-Go 20 V-Go 30 V-Go U, = 56 3 clicks /meal Consider 1 click with snack. 1 click = 2 of insulin. 4 clicks /meal 5 clicks /meal U, = 66 Additional considerations for V-Go initiation dose: Adherence to current insulin regimen Blood glucose levels Titration guidance 1. Optimize bolus If mealtime glucose remains elevated, add an additional click (2 units) 2. Titrate basal If bolus is optimized and A1c or fasting glucose remains elevated, adjust V-Go basal dose Recommended to evaluate insulin within 2-5 days of initiating V-Go and to ensure that patients have a plan to manage hypoglycemia and hyperglycemia. 1 click = U, = You can only click the Bolus Delivery Button 18 times in every 24-hour period, for up to 36 U/day. Each click of the Bolus Delivery Button delivers 2 of insulin. 76 * Individual needs may vary. Understand the total daily dose of insulin your patient is actually taking with their current insulin regimen versus what is being prescribed. Selecting the correct V-Go option may lessen the risk of hypoglycemia (low blood sugar). It is common practice to reduce the total daily insulin dose when starting a patient on continuous subcutaneous insulin infusion therapy and this reduction should be considered when starting a patient on V-Go. 2

3 Write 2 prescriptions 1 V-Go device erx Rapid-acting insulin erx Select the appropriate V-Go option Example: For V-Go device Rx: V-Go Size: 20 U, 30 U, 40 U Package Size: Each Sig: Use 1 V-Go for 24 hours as directed Disp: #30 Dosage form: Device U-100 rapid-acting insulin 1* 2 10 ml vials for V-Go ml vials for V-Go ml vials for V-Go 40 Example : For V-Go 30 insulin erx Sig: Inject subcutaneous daily Disp: #3 x 10 ml vials required per month for use in V-Go 30. Total daily dose will vary. Pharmacy Notes: Per FDA labeling, V-Go 30 requires 3 vials of insulin per month * A U-100 fast-acting insulin should be used with V-Go. Humalog (insulin lispro [rdna origin] injection) and NovoLog (insulin aspart [rdna origin] injection) have been tested by Valeritas, Inc. and found to be safe for use in V-Go. 1 Be sure to click Humalog or NovoLog. Click unstructured and type in the Sig, Disp, and Pharmacy Notes manually. Humalog is a registered trademark of Eli Lilly and Company. NovoLog is a registered trademark of Novo Nordisk A/S. 4

4 Review the ease of using V-Go 3 V-Go Customer Care Fill Patients fill each V-Go with insulin. 1 VCC provides comprehensive training and benefits for you and your patients. Dedicated representatives are available 24/7 to provide 1-on-1 support to your patients. V-Go Training (Fill, Wear, Go) Wear Patients press the V-Go device to their skin and press the Needle Button. Basal insulin administration begins immediately. 1 Personal Reimbursement Determination Co-pay Card Activation Pharmacy Support Go Patients press the Bolus Ready Button and Bolus Delivery Button at mealtimes. 2 of prandial insulin are administered with each click. 1 For all steps, see the multimedia resources at FAQs Follow-up Calls to help patients stay on track with treatment Call VCC at Ensure that patients understand basal-prandial therapy and that they have a plan to manage hypoglycemia and hyperglycemia. Valeritas does not give medical advice about insulin therapy. Patients should discuss all medical therapies with you and follow your instructions. 6

5 For patients uncontrolled on multiple daily injections of insulin V-Go Easy to start, easy to use Prescribe V-Go and rapid-acting insulin * Educate patients about V-Go ease of use with several training options Support patients with V-Go Customer Care at A co-pay reduction card is available for commercially insured patients. Go to Important Risk Information: If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Disposable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing. * A U-100 fast-acting insulin should be used with V-Go. Humalog (insulin lispro [rdna origin] injection) and NovoLog (insulin aspart [rdna origin] injection) have been tested by Valeritas, Inc. and found to be safe for use in V-Go. 1 References: 1. Instructions for Patient Use. Valeritas; Data on File. Valeritas, Inc Rosenfeld CR, Bohannon NJ, Bode B, et al. The V-Go insulin delivery device used in clinical practice: patient perception and retrospective analysis of glycemic control. Endocr Pract. 2012;18(5): V-Go is a registered trademark of Valeritas, Inc. ART-712 Rev D 04/ Valeritas, Inc.